Meta-analysis showed that compared with no use of IL-6 monoclonal antibody to prevent CRS, IL-6 monoclonal antibody was given to patients at 8 mg/kg one hour before CAR-T cell infusion, which reduced the incidence of CRS [RR: 0.41 95% confidence interval (0.20, 0.86) I[2] = 0.0% <i>P</i> = 0.338 <i>z</i> = -2.369 (<i>p</i> = 0.018)]. Here, IL6 is linked to congenital rubella syndrome.